MENU
ALGS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Aligos Therapeutics (ALGS) Ownership - Who owns Aligos Therapeutics?
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company... Show more
Profile
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
43.66M
P/E Ratio
N/A
Total Cash
56.94M
Projected Growth
N/A
Total Debt
8.38M
Revenue
3.95M
Risk (Beta)
2.36
Dividend Yield
N/A
Total Cash/Share
9.31
Total Debt/Equity
N/A
Revenue/Share
0.63 USD as % of share price
Fundamentals
ALGS
Capitalization
43.7M
P/E Ratio
N/A
Risk (Beta)
2.36
Dividend Yield
N/A
Total Cash
56.9M
Total Cash/Share
9.31
Total Debt
8.38M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.63%
Revenue
3.95M
ROE
N/A
Book Value
-28.97M
P/B Ratio
0.93
Cash Flow
N/A
Earnings
-20.94
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
2.86
Current Revenue Per Employee
8985.71
Dividends Per Share - Security
N/A
EBITDA
-86.53M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-118.41
Shares Held By Institutions
66.4M
Shares Outstanding - Current
6.11M
Total Liabilities
99.1M
Total Volume MTD
N/A
Value
1
Gain YTD
-82.078
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com